APP and early-onset autosomal dominant Alzheimer disease: In this context, our study aimed to compare the potential of low-dose, long-term treatment with fullerene C60 and its water-soluble derivative fullerenol C60(OH)24, administered orally in equimolar concentrations (0.1 mg/kg/day and 0.15 mg/kg/day, respectively), to target key Alzheimer’s disease hallmarks in APP/PS1 mutant mice as potential preventive treatments for familial AD.